new developments in renal drug transport · mate2-k 34 0.0026 lepist e.i. et al. kidney...

New Developments in Renal Drug Transport

Adrian S. Ray, Ph.D.Senior Director, Clinical Research

Gilead Sciences, Inc. Foster City, CA, USA

International Transporter Consortium Workshop 3 (ITCW3) - Transporters in Drug Development Pre-conferenceMarch 13-14, 2017, Washington DC

Renal EliminationContribution of Secretion and Filtration

Adapted from Morrissey, K.M. et al. Annu Rev Pharmacol Toxicol 2013,53:503-29

PassiveFiltration

ActiveSecretion

Glomerulus

Proximal Tubule

Proximal TubuleTransporter Expression

Adapted from Lepist E.I. and Ray A.S. Expert Opin Drug Metab Toxicol 2012,8:433-48

Blood (Basolateral) Urine (Apical)

Na+NaDC3

MATE1,MATE2-KH+

OC+

OCTN1,2carnitine or ergothioneine

H+ or OC+

MRP2,4,BCRPOA-

OATP4C1 OA-

OA- OAT4,10

OCT2 OC+

H+

peptides PEPT1,2

ATP

K+Na+

Na,K-ATPase

OAT1,3 -ketoglutarateOA-

ENT1,2 nucleosidesnucleosides

nucleosides/monoamines

OA-

-ketoglutarate

URAT1OA-/Cl-

H+

Na+ NHE3

H+ H+-ATPase

CNT1,2,3nucleosides Na+ or H+

ENT1,PMAT

urate

ATP

P-gpOC+

OAT2 OA-

OC+ THTR1,2

ATP

ATP

SGLT2glucose Na+

GLUT9burateglucose

GLUT9a urateglucose

nucleosides/monoamines

LAT1,2 amino acidNPT2aphosphate

Na+

Proximal Tubule

Creatinine Renal Transport is ComplexUptake, Secretion and Reabsorption

UrineProximal Tubule

OAT2

Blood

MATE2-K

MATE1

Over a half dozen transporters have been implicated

*evidence in rodents

Oat2*

THTR1/2

OCT2

Oat3*

OCT3

Imamura Y. et al. Clin Pharm Ther 2011, 89:8108; Vallon V. Am J Physiol Renal Physiol 2012, 302:F1293-9; Lepist E.I. et al. Kidney International 2014, 57(10):4982-9; Shen H. et al. Drug Metab Dispos 2015, 45(2), 228-36

OAT4

Clinical RelevanceDrugs Reported to Affect Serum Creatinine

Class Drug

Antacid Cimetidine

Famotidine

Antibiotic DX-619

PA-824

Trimethoprim

Antiparasitic Pyrimethamine

Antiviral Dolutegravir

Rilpivirine

Pharmacoenhancer Cobicistat

Ritonavir

Cardiovascular Amiodarone

Dronedarone

Ranolazine

Thrombin inhibitor AZD0837

Oncology Imatinib

Lepist EI. et al. Kidney International 2014, 57(10):4982-9; Chu X., et al. Drug Metab Dispos 2016, 44(9):1498-509

Clinical Relevance of Renal InteractionsAdverse Drug-Drug Interactions

Cimetidine (400 mg) reduced dofetilide renal clearance by 33% Increased ∆QTc corresponding with exposure

Dofetilide Pharmacokinetics

Placebo150 mg rantidine BID100 mg cimetidine BID400 mg cimetidine BID

[Dof

etili

de] (

ng/m

L)

Time (h)

Abel S. et al. Br J Clin Pharmacol 2000,49:64-71

Relative Contribution of Tubular SecretionEffect of Renal Impairment

16%36% 48%

Contribution to Creatinine elimination:

Glomerular Filtration Tubular Secretion

Shemesh O. et al. Kidney Int. 1985,28:830-8

In mice, cisplatin induced nephrotoxicity is increased by MATE1-/- and the inhibitor ondansetron

Clinical Relevance of Renal InteractionsOndansetron and Cisplatin

Cisplatin induced nephrotoxicity in wild type and MATE1 KO mice

Adapted from Li Q. et al. Toxicology Applied Pharmacol. 2013

WT MATE1-/-

P < 0.05

P < 0.001

Regulatory GuidanceRenal Transporters

Blood (Basolateral) Urine (Apical)

MATE1,MATE2-K

H+OC+

BCRPOA-

OCT2 OC+

OAT1,3 OA-

ATP P-gpOC+

ATP

Proximal Tubule

FDAEMA

PMDA

PMDA

FDA Draft Guidance on Drug Interactions Studies. Issued: Feb 2012; EMA Guidelines on Investigation of Drug Interaction Studies. Issued: July 2012; PMDA Drug Interaction Guideline for Drug Development and Labeling Recommendations (Draft for Public Comment). Issued: Jan 2014

FDA EMA PMDACut-Off >1.10 (10x) >1.02 (50x) >1.25 (4x)

1 + [I1]/IC50[I1] = Fraction unbound (Fu) plasma Cmax where Fu < 1% use 1%

Efficient transport by OAT2 >> OCT2

Creatinine Renal Transport is ComplexBasolateral Uptake – Role of OAT2?

Lepist E.I. et al. Kidney International 2014, 57(10):4982-9

Shen H. et al. Drug Metab Dispos 2015, 45(2), 228-36

Rat

e (p

mol

/min

/mg/

prot

ein)

[Creatinine](µM)

2,000 4,000 6,000 8,000

10,000

20,000

10,000

Vmaxpmol/min/mg

KmµM

EfficiencyµL/min/mg

OAT2 24,987 795 31.4

OCT2 17,546 18,771 0.93

OAT2 is ~30-fold more efficient creatinine transporter than OCT2

OAT2

OCT2

Creatinine TransportKinetics

Kidney TransportersQuantitative Proteomics

Prasad B. et al. Drug Metab Dispos. 2016, 44:1920-4

8-fold

Perpetrator Most Affected Transporter

Creatinine (mg/dl)

Metformin(∆AUC) Ref

Pyrimethamine MATE1/2-K ↑0.24 ↑35% Kusuhara et al. Clin Pharmacol Ther 2011

Trimethoprim MATE1/2-K ↑0.28 ↑37% Grun et al. Br J Clin Pharmacol 2013

Cimetidine MATE1 ↑0.37 ↑50% Somogyi et al. 1987

Famotidine MATE1 ↑0.11 ↔ Hibma et al. Clin Pharmacokinet 2016

Rilpivirine MATE2-K ↑0.10 ↔http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf

Dolutegravir OCT2 ↑0.11 ↑79% (QD)↑145% (BID)

Song et al. J Int AIDS Soc 2014

Ranolazine OCT2 ↑0.10 ↑37% (500 mg)↑79% (1000 mg)

Zack J. et al. ClinPharmacol Drug Dev 2015

Clinical Evidence for a Role of OAT2Creatinine versus Metformin

Clinical Drug-Drug InteractionFamotidine Effect on Creatinine and Metformin

Hidma J.E. et al. Clin Pharmacokinet 2016,55:711-21

Transporter IC50 (µM) [I1]/IC50

OCT1 19 0.015OCT2 66 0.053

MATE1 0.25 4.0MATE2 2.5 0.40

[I1] = unbound Cmax 1.0 µM

S

NN

S

N

NH2

S NH2

O

O

H2N

H2N

Serum Creatinine (mg/dL)

Metformin (∆AUC)

↑0.11** ↔

Effect of 800 mg Famotidine in Healthy Volunteers (n = 12)

Bioavailability Renal Secretion

↑1.24-fold** ↑1.36-fold**P<0.05,**P<0.01

Significant increase in Metformin pharmacodynamic effect also observed

~


OAT1 2.12 0.04OAT3 1.97 0.04OCT2 1.93 0.04

MATE1 6.34 0.01[I1] = Unbound Cmax = 80 nM

Little or no potential for clinically relevant inhibition– Lack of OAT1/3 interaction confirmed by lack of effect on PAH

and TFV in clinical studies

Reese M.J. et al. Drug Metab Dispos 2013,41:353-61

Renal Transporter InhibitionDecision Tree Analysis

Transporter InhibitionDolutegravir Inhibition of OCT2

Lepist E.I. et al. Kidney International 2014,86:350-7

OCT2 Inhibition

DolutegravirIC50 = 66 nM

TEA

upta

ke (%

con

trol

)

More than 20-fold more potent than published value– Similar MATE1 IC50 (4.67 µM) to that previously reported

Transporter InhibitionEffect of Serum Protein

Dolutegravir Inhibition of OCT2-Dependent Metformin Transport

Human Serum

IC50(µM)

0% (Buffer) 0.085

5% 0.10

10% 0.20

25% 0.71

100% 1.4

Estimated IC50 = 11 µM (Fu 0.8%)

Cimetidine has same IC50 in buffer and 100% serums (~ 80 µM)

Based on metformin total clearance (0.4 L/h/kg) and GFR (0.11 L/h/kg), inhibition of tubular secretion of 60% for 1.79-fold increase in metformin

Inhibition of OCT2 by DolutegravirPrediction Based on IC50 in Human Serum

Multidose pharmacokinetics from Greener B.N. J Acquir Immune Defic Syndr 2013,64:39-44

Time (h)

Dol

uteg

ravi

r (μM

)

Dolutegravir Pharmacokinetics

HS IC50

Little or no potential for clinically relevant inhibition– Weak inhibition of cationic transporters

Renal Transporter InhibitionDecision Tree Analysis


OAT1 >100 <0.001OAT2 >100 <0.001OAT3 6.6 0.014MRP2 71 0.0012MRP4 24 0.0037[I1] = unbound Cmax 90 nM


OCT2 14 0.0064OCT3 12 0.0075

OCTN1 2.5 0.036MATE1 1.9 0.047

MATE2-K 34 0.0026


Reversible decrease in creatinine secretion in the absence of an effect on renal function

Inhibition of Creatinine SecretionCobicistat

German P. et al. J Acquir Immune Defic Syndr 2012, 61(1):32-40

n = 12*p<0.05

-9.9 mL/min*

Actual versus EstimatedGlomerular Filtration Rate


Facilitated Inhibitor AccumulationCobicistat Transport by OCT2

Mean ± SD; N = 3 independent experiment**, P < 0.005; ****, P < 0.0001; Students t-test

OCT2 Transport

Assay SystemsMultiple Transfection Model

Creatinine Secretion

OAT2OCT2OCT3MATE1MATE2-K

Tran

scel

lula

r Tra

nspo

rt(p

mol

/min

/cm

2 )

Zhang, X.et al. AAPS Workshop, Bethesda, MD, March 17-20, 2013

% C

ontro

l

CimetidineVehicle

OCT2 potentiates cimetidine inhibition of MATE1

Proximal Tubule Model SystemsPrimary Proximal Tubule Cells

Billington S. et al. AAPS, San Diego, California, November 2-6, 2014

Secretory transport of Tenofovir

MRP4

OAT1

Proximal Tubule

Blood (Basolateral)

Urine (Apical)

ATP

OAT3

OATP4C1???

Proximal Tubule Model Systems3D Bioprinting

King SM. Front Physiol 2017, in press

Basal interstitium– Renal fibroblasts and Endothelial cells (HUVEC)

Epithelium– Monolayer of primary polarized proximal epithelium cells

Conclusions

Clinically significant renal DDIs are rare but are difficult to predict, underappreciated and may be more severe in sensitive populations

Renal transport pathways are complex– Fractional transport (ft) often spread across multiple

transporters– Involvement of transporters not often studied

Need for more holistic models to study potential for renal drug-drug interactions– Actual victim/perpatrator– Addition of plasma proteins– Multiple transfection and PPT systems

Thank you for your attention !

Kathy GiacominiXiaomin Liang

Leslie Benet

Yong HuangJason Baik

Alan KosakaJane Huang

Xuexiang Zhang

Eve-Irene LepistMarilyn Giacomini

Jia HaoKelly MacLennan

Jolyn Twelves

Thomas Murphy

Colin BrownSarah Billington

new developments in renal drug transport · mate2-k 34 0.0026 lepist e.i. et al. kidney...

Documents